Abstract 221P
Background
Concurrent chemoradiation (CRT) represents a standard treatment for several advanced cancers including non-small cell lung cancer (NSCLC) based on its synergistic cytotoxic effects. CRT followed by durvalumab (anti-PD-L1 antibody) therapy has become standard maintenance therapy for locally advanced NSCLC. However, this combination is still ineffective in most patients, illustrating the need to better understand the immunological effects driven by CRT, which are less known. This study aims at investigating the CRT-induced tumor reactive T cell responses as well as transcriptomic changes.
Methods
Blood samples were collected from 43 NSCLC patients at baseline, during CRT, and three months after CRT. For patients received durvalumab after CRT, additional samples were taken at three months and one-year post-durvalumab. Multiparametric immunologic analyses were conducted by IFN-γ ELISpot, RNA-Seq, and qRT-PCR.
Results
A transient decrease in specific T cell responses against TERT and NY-ESO-1 was observed during CRT, followed by an increase after CRT in 60.0% and 40.0% patients, respectively. There was no significant change in antiviral T cell responses before and during CRT. The application of durvalumab can enhance the anti-tumor specific T cell response of CRT. T cell transcriptomic analysis revealed 105 and 422 genes were upregulated during and after CRT compared to baseline, and 81 and 60 genes were downregulated, respectively. There were 16 genes downregulated during CRT but upregulated after which were enriched in inflammatory pathways. Analysis of immune-related genes showed T cell activation, cytolytic, and exhaustion markers were downregulated during CRT but upregulated afterward. RNA-Seq findings were corroborated by qRT-PCR, which identified the relationships between CD8a expression and cytotoxic genes as well as activation markers. TCR-Seq analysis demonstrated CRT induced changes in specificity and diversity of T cell repertoire, with reduced clonotype sharing between patients and an expansion of T cell clones post CRT.
Conclusions
These findings indicate the systemic immunological changes induced by CRT in NSCLC patients support the rationale to use checkpoint inhibitors as adjuvant therapy post CRT.
Legal entity responsible for the study
Olivier Adotevi.
Funding
Ligue Contre Le Cancer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session